J&J is seeking a diverse population for the Covid-19 vaccine trial called the EMSEMBLE study. There are two study sites in the Chicago area.

Research has shown that certain diseases and medications may impact people differently based on their age, gender, and genetic background, including race and/or ethnicity. For example, COVID-19 has disproportionately impacted both older people and minority populations. Therefore, clinical research studies require large and diverse numbers of volunteers to participate in a single study, sometimes thousands are needed to obtain reliable information. This helps ensure that medications and vaccines are generally safe and work for different types of people, especially those most impacted by the disease or illness.

Johnson & Johnson is committed to partnering with national and local organizations, working with community leaders and developing important educational materials and resources to reach populations that have been disproportionately impacted by the pandemic and emphasize the important role clinical trial participation plays in helping to develop safe and effective vaccines for many types of people.

As we continue to actively recruit individuals from diverse populations for our clinical trials, we welcome your ongoing insights about how we might appropriately share information and engage with your stakeholders regarding participation in the ENSEMBLE study. A flyer, a brochure and a participant poster for the ENSEMBLE study are attached above.

I also encourage you to visit our website, www.researchincludesme.com, which provides educational materials on the clinical trial process for a non-clinical audience, information on the safeguards in place today to help protect clinical trial participants, and guidance on how to find a local clinical trial. There are two trials in the Chicago area. They are listed below. Participants can also link to ENSEMBLEstudy.com to find more sites. This is a fluid situation, so if sites are showing they are not enrolling, we encourage possible participants to reach out more than once, if necessary.

<table>
<thead>
<tr>
<th>The University of Chicago Medicine</th>
<th>Actively Enrolling</th>
<th>5835 S Cottage Grove C278</th>
<th>Chicago</th>
<th>Illinois</th>
<th>60637</th>
<th>United States</th>
<th>7738349992</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rush University Medical Center-Chicago</td>
<td>Actively Enrolling</td>
<td>1653 W Congress Pkwy</td>
<td>Chicago</td>
<td>Illinois</td>
<td>60612</td>
<td>United States</td>
<td>3125632902</td>
</tr>
</tbody>
</table>

Should you wish to learn more specifically about the Phase 3 study of our investigational COVID-19 vaccine and our commitment to safety and transparency, you will find additional help here.

As always, should you have any questions, please don’t hesitate to reach out to your Janssen/J&J Healthcare Policy and Advocacy Director, Debbie Bandy.

Thank you,

Deborah Bandy
Director, Healthcare Policy and Advocacy
Johnson and Johnson Health Care Systems
DBandy2@its.jnj.com